CJC-1295 + Ipamorelin Benefits, Safety & Buying Advice 2025


CJC-1295 + Ipamorelin Benefits, Safety & Buying Advice 2025

CJC-1295 and Ipamorelin



CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce more endogenous growth hormone (GH).

Ipamorelin is a selective growth hormone secretagogue (GHS) that mimics ghrelin, binding to its receptor on pituitary cells and further amplifying GH release. When combined, these two peptides create a synergistic effect: CJC-1295 provides the stimulus signal while Ipamorelin enhances the response, leading to sustained elevations of circulating growth hormone over several days.



Jump to



Why you should trust us?



Our review is based on peer-reviewed studies, clinical trial data, and expert consensus from endocrinology and sports medicine. We cross-checked all product information with regulatory filings and reputable suppliers, ensuring that the guidance reflects current best practices in 2025. Readers can rely on our evidence-based approach to navigate the complex landscape of peptide therapies.



What are CJC-1295 and ipamorelin?



CJC-1295 (also known as Met-Enkephalin-derived GHRH analog) is engineered for a longer half-life than native GHRH, allowing once-weekly dosing. Ipamorelin is a pentapeptide that selectively activates the ghrelin receptor without significant orexigenic or cortisol-stimulating effects. Together they form a "dual-agonist" protocol widely used in anti-aging and body-building communities.



Why are CJC-1295 and ipamorelin used together?



Using them in tandem maximizes GH secretion while minimizing the need for higher doses of each peptide alone. The dual mechanism reduces peak hormone spikes, leading to smoother hormonal profiles, lower side-effect risk, and better patient adherence.